Top

Published in:

01-08-2011 | Original Article

Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer

Authors: Matthias Choschzick, Egbert Oosterwijk, Volkmar Müller, Linn Woelber, Ronald Simon, Holger Moch, Pierre Tennstedt

Published in: Virchows Archiv | Issue 2/2011

Abstract

Carbonic anhydrase IX (CAIX) is a strictly membranous expressed metalloenzyme involved in cell adhesion, pH homeostasis, and cancer progression. This study was designed to assess the role of CAIX in primary ovarian cancer. Two hundred five well-characterized primary ovarian carcinomas were analyzed on a tissue microarray. CAIX expression was determined by immunohistochemistry using a four-step scoring system. Moderate and strong membranous CAIX expression was found in 37 out of 205 (18%) of all assessable ovarian cancer specimens. High levels of CAIX expression were related to mucinous and endometrioid phenotype of ovarian carcinomas (p < 0.05). There was no association between CAIX overexpression and tumor stage, grading, and mitotic count of ovarian carcinomas (p > 0.05). In univariate Cox regression analysis, advanced tumor stage (p < 0.01), high tumor grade (p = 0.017), high mitotic count (p = 0.025), and high CAIX expression levels (p = 0.031) were correlated to shorter overall patient survival. High pT stage (p = 0.036) and CAIX overexpression were connected to poor clinical outcome in endometrioid ovarian carcinomas. Multivariate Cox regression hazard analysis comprising tumor stage, tumor grade, mitotic count, and CAIX expression revealed pT2/3 stage and CAIX overexpression (scores 2 and 3) as independent prognostic markers in ovarian cancer (p < 0.01, each) as well as in the subgroup of endometrioid carcinomas (p < 0.05, each). In conclusion, CAIX is overexpressed in a substantial proportion of mucinous and endometrioid ovarian carcinomas and connected to poor patient outcome. Our data support the potential therapeutic benefit of newly developed targeting antibodies in advanced ovarian cancer.

Zavada J, Zavadova Z, Pastorekova S et al (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54:268–274PubMedCrossRef

Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164–167PubMedCrossRef

Robertson N, Potter C, Harris AL (2004) Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64:6160–6165PubMedCrossRef

Kaluz S, Kaluzova M, Liao SY et al (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795:162–172PubMed

Ivanov S, Liao SY, Ivanova A et al (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919PubMedCrossRef

Hussain SA, Ganesan R, Reynolds G et al (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96:104–109PubMedCrossRef

Klatte T, Seligson DB, Rao JY et al (2009) Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115:1448–1458PubMedCrossRef

Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399PubMed

Swinson DE, Jones JL, Richardson D et al (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:473–482PubMedCrossRef

10.

Pfisterer J, du Bois A (2007) [Therapeutic standards for ovarian cancer]. Pathologe 28:222–228PubMedCrossRef

11.

Hynninen P, Vaskivuo L, Saarnio J et al (2006) Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49:594–602PubMedCrossRef

12.

Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36:98–105PubMed

13.

Partridge EE, Phillips JL, Menck HR (1996) The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 78:2236–2246PubMedCrossRef

14.

Bubendorf L, Nocito A, Moch H et al (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79PubMedCrossRef

15.

Ruiz C, Seibt S, Al Kuraya K et al (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118:2190–2194PubMedCrossRef

16.

Torhorst J, Bucher C, Kononen J et al (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256PubMedCrossRef

17.

Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160PubMed

18.

Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107:1053–1062PubMedCrossRef

19.

Kaluz S, Kaluzova M, Chrastina A et al (2002) Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res 62:4469–4477PubMed

20.

Kopacek J, Barathova M, Dequiedt F et al (2005) MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta 1729:41–49PubMed

21.

Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96:4240–4245PubMedCrossRef

22.

Shayesteh L, Lu Y, Kuo WL et al (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99–102PubMedCrossRef

23.

Zavada J, Zavadova Z, Zat’ovicova M et al (2003) Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89:1067–1071PubMedCrossRef

24.

Mulders P, Bleumer I, Debruyne F et al (2004) Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Urologe A 43(Suppl 3):S146–S147PubMed

25.

Bauer S, Oosterwijk-Wakka JC, Adrian N et al (2009) Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 125:115–123PubMedCrossRef

26.

Stillebroer AB, Mulders PF, Boerman OC et al (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58:75–83PubMedCrossRef

27.

Wilex: Phase III ARISER Study (Adjuvant RENCAREX®Immunotherapy Phase III trial to Study Efficacy in non-metastatic RCC). http://www.wilex.de/R&D/RENCAREX_PhaseIII.htm

Title: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer
Authors: Matthias Choschzick
Egbert Oosterwijk
Volkmar Müller
Linn Woelber
Ronald Simon
Holger Moch
Pierre Tennstedt
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 2/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1105-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Chromosomal imbalances in carcinoma showing thymus-like elements (CASTLE)

Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry

Mediastinal fetal rhabdomyoma in nevoid basal cell carcinoma syndrome: a case report and review of the literature

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

Growth patterns of lung metastases from sarcomas

Primary malignant tumour of the lung with neuroendocrine and melanoma differentiation